|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2003-11-7
|
|
pubmed:abstractText |
To evaluate the safety and efficacy of various doses of recombinant glucagon-like peptide-1 (7-36) amide (rGLP-1) administered subcutaneously (s. c.) via bolus injection or continuous infusion to lower fasting serum glucose (FSG) levels in subjects with type 2 diabetes treated by diet, hypoglycemic drugs, or insulin injection.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Glucagon,
http://linkedlifedata.com/resource/pubmed/chemical/Glucagon-Like Peptide 1,
http://linkedlifedata.com/resource/pubmed/chemical/Glucagon-Like Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Metformin,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Placebos,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonylurea Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/glucagon-like peptide 1 (7-36)amide
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0018-5043
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
611-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:14605997-Blood Glucose,
pubmed-meshheading:14605997-Cross-Over Studies,
pubmed-meshheading:14605997-Diabetes Mellitus, Type 2,
pubmed-meshheading:14605997-Double-Blind Method,
pubmed-meshheading:14605997-Drug Therapy, Combination,
pubmed-meshheading:14605997-Fasting,
pubmed-meshheading:14605997-Glucagon,
pubmed-meshheading:14605997-Glucagon-Like Peptide 1,
pubmed-meshheading:14605997-Glucagon-Like Peptides,
pubmed-meshheading:14605997-Humans,
pubmed-meshheading:14605997-Hypoglycemic Agents,
pubmed-meshheading:14605997-Insulin,
pubmed-meshheading:14605997-Metformin,
pubmed-meshheading:14605997-Peptide Fragments,
pubmed-meshheading:14605997-Placebos,
pubmed-meshheading:14605997-Recombinant Proteins,
pubmed-meshheading:14605997-Sulfonylurea Compounds
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
|
|
pubmed:affiliation |
Restoragen, Inc., Lincoln, Nebraska, USA. marioe@pacbio.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
